



# Editor's Welcome

Dear colleagues!

We present to your attention the next, thirty-ninth issue of the International Heart and Vascular Disease Journal that includes the leading, original, review articles, and ESC Congress 2022 report as well.

The results of a clinical population study to evaluate the characteristics of aortic valve stenosis and its association with a biomarker for heart failure and atrial fibrillation are presented in the "Leading Article" section. In a study of 2380 patients aged 35–69 years, the prevalence of high-gradient aortic stenosis increased with age. Biomarkers of heart failure and atrial fibrillation were associated with aortic valve area after correcting for the presence of heart failure by history, age and sex.

Three publications are presented in the "Original Articles" section. The first article evaluates clinical and functional parameters, markers of myocardial and renal dysfunction, and the ability of multimarker models to predict adverse outcomes in patients with chronic heart failure with preserved left ventricular ejection fraction, type 2 diabetes mellitus, and chronic kidney disease. Patients with a combination of the three diseases have severe clinical, functional disorders of the cardiovascular system and carbohydrate metabolism. The model that included NT-proBNP and sST2 levels had the best prognostic value. The second article presents a retrospective study of 720 patients who underwent aortic valve neocuspidation surgery. Among the different age categories, younger age was found to be a risk factor for reoperation. The third article analyzed echocardiographic data and N-terminal brain natriuretic peptide levels during the hospital phase of treatment in patients with acute ST-elevation myocardial infarction. It was shown that high-risk patients on the GRACE scale have older age, reduced left ventricular ejection fraction, and the most severe changes in diastolic dysfunction.

Two papers are presented in the "Review Articles" section. The first article presents a systematic review of literature data to determine the impact of early prescription of sodium-glucose cotransporter type 2 inhibitors in patients with acute decompensation of chronic heart failure on the immediate prognosis, as well as the effect of therapy on reducing the level of heart failure markers at the hospital stage. The second article focuses on the problems of percutaneous coronary intervention in cancer patients. This procedure is associated with an increased risk of bleeding, in-hospital and long-term mortality, and the need for repeat revascularisation. Proper management of cancer patients with concomitant coronary artery disease can reduce the risk of periprocedural complications during revascularisation.

The Cardioprogress Foundation report presents the results of the most important clinical trials and meta-analyses shown at the European Society of Cardiology Congress 2022.

We invite everybody to collaborate with the journal. We are waiting for your original papers, review articles, discussions, and opinions about problems, treatment and prophylaxis recommendations.

**Mekhman N. Mamedov**

Editor-in-Chief

President of the "Cardioprogress" Foundation